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PURPOSE. To determine the effect of molecular weight (MW) on the concentration of plasma-
derived proteins in aqueous humor and to estimate the plasma-derived and eye-derived
fractions for each protein.
METHODS. Aqueous humor and plasma samples were obtained during cataract surgery on an
institutional review board–approved protocol. Protein concentrations were determined by
ELISA and quantitative antibody microarrays. A total of 93 proteins were studied, with most
proteins analyzed using 27 to 116 aqueous and 6 to 30 plasma samples.
RESULTS. Plasma proteins without evidence of intraocular expression by sequence tags were
used to fit a logarithmic model relating aqueous-plasma ratio (AH:PL) to MW. The log(AH:PL)
appears to be well predicted by the log(MW) (P < 0.0001), with smaller proteins such as
cystatin C (13 kDa) having a higher AH:PL (1:6) than larger proteins such as albumin (66 kDa,
1:300) and complement component 5 (188 kDa, 1:2500). The logarithmic model was used to
calculate the eye-derived intraocular fraction (IOF) for each protein. Based on the IOF, 66
proteins could be categorized as plasma-derived (IOF<20), whereas 10 proteins were
primarily derived from eye tissue (IOF >80), and 17 proteins had contribution from both
plasma and eye tissue (IOF 20–80).
CONCLUSIONS. Protein concentration of plasma-derived proteins in aqueous is nonlinearly
dependent on MW in favor of smaller proteins. Our study demonstrates that for proper
interpretation of results, proteomic studies evaluating changes in aqueous humor protein
levels should take into account the plasma and eye-derived fractions.
Keywords: aqueous humor, blood-aqueous barrier, proteins, plasma
Identification of the protein constituents of body fluid canlead to a better understanding of normal physiology and
improve our understanding of the molecular underpinnings of
common diseases. The aqueous proteome is of particular
interest as it might be altered in many ocular diseases. Previous
molecular analysis of the aqueous humor (AH) have mainly
focused on the protein composition and the number of
proteins in the Human Eye Proteome Project has increased to
827 proteins in 2018.1
To better understand the influence of the AH proteome on
ocular physiology and disease, it is critical to differentiate
between aqueous proteins derived from ocular structures and
plasma-derived proteins that diffuse into AH. Although plasma-
derived proteins may exert influence on ocular physiology,
their levels within AH are highly dependent on their plasma
levels. In contrast, proteins derived from intraocular structures
are more likely to be internally regulated and hence are more
likely to have direct impact on ocular function or be related to
ocular pathophysiology.
In contrast to plasma, the AH is relatively free of proteins, so
as to maintain clarity of vision. Plasma proteins are restricted
from entering AH by the blood-aqueous barrier, although a
significant portion of AH proteins originates from plasma. The
blood-aqueous barrier is formed by the tight junctions of the
nonpigmented epithelia of the ciliary body and posterior iris,
and the nonfenestrated iris capillaries. Plasma proteins can pass
through the fenestrated capillaries of the ciliary body but are
prevented from entering the posterior chamber by the ciliary
body nonpigmented epithelia. Similarly, plasma proteins
circulating through iris capillaries are blocked from entering
the iris stroma by the iris capillary vessel walls.2,3
However, plasma proteins that pass through the fenestrated
capillaries of the ciliary body can diffuse through the ciliary
body stroma into the iris stroma at the iris root. Because the
anterior surface of the iris is not bound by any nonpenetrable
barrier, plasma proteins within the iris stroma can then diffuse
into the AH within the anterior chamber.4,5
According to Fick’s laws of diffusion, small proteins diffuse
through media more rapidly than large proteins. Thus, we
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hypothesize a size-dependent relationship between the con-
centrations of proteins in AH relative to their plasma
concentrations. A similar process has been described for
plasma proteins entering the cerebrospinal fluid (CSF) through
the blood-CSF barrier.6,7 Previous proteomics studies on
AH8–18 have provided insight into the protein composition
but to the best of our knowledge, a comprehensive analysis of
the combined proteome of the AH and plasma has not yet been
carried out. To test our hypothesis, we simultaneously
determined the concentrations of 93 plasma proteins within
plasma and AH and examined the effect of molecular weight
(MW) on the ratio of AH concentration to plasma concentra-
tion.
We also introduce the eye-derived intraocular fraction (IOF)
as an estimate of the proportion of each protein derived from
ocular structures. This allows us to categorize the proteins into
three groups: the proteins derived from the surrounding eye
tissue, the proteins derived from the plasma, and proteins with
contributions from both.
METHODS
This study was approved by the Indiana University Institutional
Review Board and followed the tenets of the Declaration of
Helsinki. All subjects gave informed consent after explanation
of the nature and possible consequences of the study.
Subjects
Aqueous samples were collected from eyes at the start of
cataract surgery. Eligible subjects were older than 40, had no
eye disease or disorder except cataract, had consented to
undergo cataract surgery, and were willing to participate in this
study. Exclusion criterion was prior intraocular surgery of any
type, including laser.
Sample Collection and Clinical Data
AH samples were collected at the start of surgery by inserting a
30-gauge needle through the peripheral cornea and withdraw-
ing approximately 100–250 lL of aqueous into a tuberculin
syringe. Alternatively, a paracentesis was created with a 15-
degree blade and the aqueous sample collected with a 30-
gauge cannula on a tuberculin syringe. The aqueous sample
was immediately transferred to a barcode-labeled cryotube,
placed on ice, and transported to the Biospecimen Repository
where the specimens were stored at 808C until proteomic
analysis. Clinical data and information associated with the AH
sample were entered into the caTISSUE suite software that we
have adapted for eye disease research.
Blood samples were collected in EDTA-coated vacutainers
from a subset of subjects just before the start of surgery. To
obtain platelet-poor plasma, a double spin protocol was used.
Blood samples were first centrifuged at 3000g at room
temperature for 10 minutes. The plasma was transferred to a
sterile 2-mL Eppendorf tube without disturbing the buffy coat
and subjected to a second centrifugation step at 12,000g for 10
minutes. The platelet-poor plasma was aliquoted into sterile
cryovials and stored at 808C. Samples were frozen within 2
hours of collection.
Enzyme-Linked Immunosorbent Assay
Protein concentration in aqueous and plasma samples was
measured using commercial ELISA kits (Abcam, Cambridge,
UK; Raybiotech, Norcross, GA, USA; LifeSpan BioScience,
Seattle, WA, USA) as per the manufacturer’s instruction.
Standards, AH samples, and diluted plasma samples were
added to 96-well plates containing highly purified protein-
specific antibodies, incubated, and washed. Protein-specific
biotinylated detection antibody was added, incubated, and
washed, followed by the addition of an enzyme substrate, then
a stop solution. Plates were read at 450 nm with a Tecan
GENios Pro Multifunction Microplate Reader (Tecan, Manne-
dorf, Switzerland). Concentration estimates were found by
fitting a four-parameter log-logistic model to a standard curve
generated alongside the experimental data using the drc
package19 in R.20
Quantitative Antibody Microarray Analysis
The proteins in AH and plasma of patients were analyzed with
the glass-slide quantitative antibody microarray platform
(Quantibody; Raybiotech), which enables the accurate con-
centration determination of multiple proteins simultaneously.
Proteins were combined in the same experiment based on
their similar expected concentration range in AH and plasma.
The proteins were screened for cross reactivity by the
Raybiotech support staff. Antibodies to 20 to 40 proteins,
along with positive and negative controls, were spotted onto a
glass slide in quadruplicate. Samples were assayed according to
the manufacturer’s protocol.
Briefly, the glass slides were blocked, incubated with 70 lL
of AH or plasma overnight at 48C, washed, and then incubated
with the biotin-conjugated antibodies specific for the proteins
bound to the antibody on the glass slide. The slides were
developed with streptavidin-labeled Cy3 equivalent dye and
the signal was quantified using a laser scanner (GenePix
4000A; Molecular Devices Corporation, San Jose, CA, USA) at
four different settings of the photomultiplier tube gain. These
were combined using a linear regression model, in which the
log-observed intensity at each spot was modeled as a function
of gain for unsaturated spots with intensities at or above 200.
Poor-quality spots were removed from the analysis based on
visual inspection. Data were then normalized using the positive
controls. Concentration estimates were found by fitting a four-
parameter log-logistic model to a standard curve generated
alongside the experimental data using the drc19 package in R.20
Protein Data
The theoretical MW of a protein was calculated using the
sequence of the circulating protein chain from the UniProt
Knowledgebase21,22 and the Compute pI/Mw tool of the
ExPASy bioinformatic resource portal.23 We conducted litera-
ture searches to identify the experimentally determined MW of
the circulating form of each protein and the theoretical MW
was adjusted when experimental data were available.
Statistical Analysis
For each protein, we modeled the concentration on the log
scale using a mixed effects model with fluid (AH or plasma) as
a predictor. Subjects were treated as random effects to
incorporate correlation between fluids from the same patient.
The variance was estimated separately for each fluid. From
each analysis, we obtained the concentration ratio between
aqueous and plasma (AH:PL), the standard errors associated
with each estimate, and the correlation across the two fluids.
All analyses were conducted using the nlme24 and multcomp25
packages in R.
To predict the diffusion component of AH proteins, we first
selected a subset of high-abundance plasma proteins measured
by ELISA with no evidence of intraocular expression by
sequence tags (EST) within the ciliary body,26 iris,27 cornea,28
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anterior segment, trabecular meshwork,29 lens,30 retina,31 and
RPE/choroid32 from the NEIBank sequence tag analysis
project.33–35 We then modeled AH:PL ratio, on the log scale
as a function of the MW, also on a log scale:
log10ðAH : PLÞ ¼ aþ b3 log10ðMWÞþ
The data were fit using a weighted mixed effects model in
which proteins were treated as random effects, and each
protein ratio was weighted by its standard error using the
metafor36 package in R. Using this initial model, we calculated
a 95% prediction interval for all proteins based on the MW.
To distinguish plasma-derived proteins from predominately
eye-derived proteins, the IOF was calculated for each protein
as
IOF ¼ max 0; 1  10upper bound  observed 3 100;
as described by Reiber for CSF.37,38 A final model was produced
by also including proteins measured by quantitative antibody
microarray that had an IOF of 0, no evidence of ESTs in ocular
tissue, and minimal heterogeneity in the reported MW of the
circulating plasma protein in the literature. This model was
used to produce the final estimate of the IOF for all proteins.
RESULTS
Samples were withdrawn from patients who ranged in age
from 50 to 80. Table 1 shows the demographics of the AH and
plasma samples used for the various protein analyses. Sample
size for each protein measured is summarized in Table 2 for AH
and plasma.
Analysis of AH Proteome by ELISA
To better understand the relationship between MW and AH
concentration of plasma proteins, we sought to quantitate the
concentrations of proteins that had been previously found by
liquid chromatography tandem mass spectrometry in both
aqueous8–18 and plasma.39–41 Forty proteins were selected
based on the availability of high-sensitivity ELISA needed to
detect the expected low concentration in AH. For 3 of the 40
proteins, the concentrations in AH were too low to be
adequately quantified. The concentrations of proteins in AH
versus plasma are shown in Figure 1. Relative to albumin, the
primary protein component of both aqueous and plasma, low-
MW proteins tend to be overrepresented in aqueous, whereas
high-MW proteins tend to be underrepresented.
After determining the concentration of the 37 proteins, the
ratio of AH concentration to plasma concentration (AH:PL) was
calculated. As shown in Figure 2, smaller proteins such as
cystatin C (CYTC, MW ~13 kDa) tend to have a higher AH:PL
ratio (1:5.6) than larger proteins such as albumin (ALBU, MW
~66 kDa), which had an AH:PL ratio of 1:300, and complement
component 5 (CO5, MW ~188 kDa), which had an AH:PL ratio
of 1:2500. The plot of AH:PL versus MW is shown in Figure 2.
The AH:PL of the 37 proteins is listed in Table 2.
Analysis of AH Proteome by Quantitative Antibody
Microarray
To identify additional proteins that are quantifiable in aqueous,
we screened 157 proteins by quantitative glass-slide antibody
microarrays. Of the 157 proteins analyzed in initial screening
assays, 101 proteins were not further studied: 42 proteins were
not detectable in AH, 38 proteins were at the lower detection
limit, and 21 proteins were in the linear range but were
excluded for various reasons such as cross reactivity and
plasma dilution requirements out of the range of the other
proteins.
The remaining 56 proteins were further studied using larger
sample sizes (up to 116 aqueous samples and 14 plasma
samples) with quantitative antibody microarrays. Proteins were
assigned to quantitative antibody microarray group 1 (Q1: 35
proteins) and group 2 (Q2: 21 proteins) based on dilution and
protein cross reactivity. The concentration and AH:PLs of all 56
proteins measured by quantitative antibody microarray are
included in Table 2.
Modeling AH:PL as Function of MW
Of the 37 proteins measured by ELISA, 17 that had no evidence
of intraocular expression by EST were used to fit the model.
Using this model, we calculated the IOF for all 93 proteins,
which included the 37 proteins measured by ELISA and the 56
proteins measured by the quantitative antibody microarray
(Table 2). Of the 56 proteins measured by quantitative antibody
microarray, 10 proteins with an IOF of zero and no evidence of
TABLE 1. Patient Demographics of Aqueous and Plasma Samples
AH Plasma
n Age, Median (Min, Max) % Male n Age, Median (Min, Max) % Male Proteins
Quantitative antibody microarray
Group 1 116 68.9 (45.8, 94.6) 53.4 14 68.4 (55.5, 87.4) 57.1 35 proteins (see Table 2)
Group 2 27* 72.4 (54.2, 85.7) 48.1 6 66.4 (55.5, 80.1) 33.3 21 proteins (see Table 2)
ELISA
Group 1 40 65.5 (48.6, 87.4) 50.0 24 67.1 (48.6, 87.4) 37.5 ALBU, ANGI, APOA1, APOA2, C05, C06,
C07, C09, FINC, GELS, IgG, KNG1,
TRFE
Group 2 40 68.9 (48.6, 87.4) 50.0 26 67.3 (48.6, 87.4) 46.2 A1AG, A2MG, AACT, AMBP, B2MG, CLUS,
C03, C04, CYTC, DKK3, FETUA,
HEMO, HPT, OSTP, RET4, TTHY, VTN
Group 3 30 65.2 (54.2, 82.8) 50.0 30 66.4 (53.6, 87.4) 70.0 FIB, CCL2
Group 4 40 68.9 (48.6, 87.4) 50.0 30 66.4 (53.6, 87.4) 70.0 CERU
Group 5 4 68.9 (45.8, 73.7) 25.0 4 71.0 (48.8, 76.3) 25.0 AFAM, A2GL
Group 6 5 65.1 (59.2, 71.3) 100.0 10 65.9 (48.6, 82.3) 40.0 APOC3
Group 7 12† 67.8 (55.5, 85.6) 40.0 10 73.3 (47.2, 94.1) 20.0 PEDF
* Quantitative antibody microarray group 2 was composed of six pooled AH samples, with three to six samples per pool.
† ELISA group 7 was composed of two pooled AH samples, with four and eight samples per pool.
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TABLE 2. Protein Concentrations in AH and Plasma
Protein
Symbol UniProt ID
MW,
kDa
Aqueous Concentration Plasma Concentration
ELISA
Kit
Mean
(95% CI) Units
Mean
(95% CI) Units Ratio
IOF,
% Notes
ALBU P02768 66 176 (168–185) lg/mL 54 (49.4–58.9) mg/mL 1:300 0 E1, M1 A
IGG 150 7.72 (7.52–7.92) lg/mL 4.45 (4.32–4.58) mg/mL 1:580 0 E1, M1 A
PEDF P36955 50 6.23 (1.75–2.21) lg/mL 6.14 (5.69–6.64) lg/mL 1:1 96 E7 R
TTHY P02766 55 6.13 (5.94–6.34) lg/mL 305 (296–313) lg/mL 1:50 0 E2 A
A1AG P02763, P19652 43 5.31 (5.12–5.51) lg/mL 1.21 (1.17–1.24) mg/mL 1:230 0 E2, M1 A
TRFE P02787 79.5 5.03 (4.94–5.11) lg/mL 819 (805–834) lg/mL 1:160 0 E1 A
HEMO P02790 59 2.46 (2.39–2.54) lg/mL 655 (646–664) lg/mL 1:270 0 E2, M1 A
CERU P00450 132 1.91 (1.75–2.08) lg/mL 517 (507–527) lg/mL 1:560 0 E4 A
A2MG P01023 179 1.16 (0.98–1.37) lg/mL 1.47 (1.43–1.5) mg/mL 1:3500 0 E2 A
CYTC P01034 13.34 961 (933–990) ng/mL 5.39 (5.28–5.5) lg/mL 1:5.6 0 E2 A
APOA1 P02647 56* 763 (730–797) ng/mL 2.48 (2.41–2.56) mg/mL 1:3300 0 E1 A
GELS P06396 82.8 687 (650–725) ng/mL 50.8 (49.4–52.1) lg/mL 1:75 0 E1 L
AACT P01011 57 623 (599–648) ng/mL 220 (214–225) lg/mL 1:350 0 E2 A
FETUA P02765 59 476 (456–496) ng/mL 240 (234–247) lg/mL 1:510 0 E2, M1 R
VTNC P04004 75 360 (348–374) ng/mL 370 (363–377) lg/mL 1:1000 0 E2, M1 R
DKK3 Q9UBP4 65 341 (330–353) ng/mL 61.1 (59.7–62.5) ng/mL 1:0.2 99 E2 R
CO3 P01024 185 245 (233–257) ng/mL 814 (799–828) lg/mL 1:3400 0 E2, M1 A
CLUS P10909 80 233 (223–243) ng/mL 68.1 (66.9–69.2) lg/mL 1:290 0 E2 R
AMBP P02760 26 210 (200–221) ng/mL 88.6 (86.7–90.6) lg/mL 1:430 0 E2, M1 A
CO4 P0C0L4,-5 210 187 (181–195) ng/mL 210 (205–216) lg/mL 1:1100 0 E2 A
B2MG P61769 11.7 114 (111–118) ng/mL 2.52 (2.47–2.58) lg/mL 1:22 0 E2 A
RET4 P02753 75 89.6 (85.8–93.5) ng/mL 33.6 (32.8–34.3) lg/mL 1:380 0 E2 A
HPT P00738 86* 78.5 (54.7–113) ng/mL 603 (555–654) lg/mL 1:5600 0 E2 A
CO9 P02748 71 60.8 (57.9–63.8) ng/mL 60.9 (59.6–62.2) lg/mL 1:1000 0 E1, M1 A
FIB P02671,-5,-9 340 58.7 (53.8–64) ng/mL 4.08 (3.97–4.19) mg/mL 1:71000 0 E3, M1 A
OSTP P10451 44 58.7 (55.6–61.9) ng/mL 5.43 (5.32–5.54) ng/mL 10.7:1 99 E2 R
CO7 P10643 110 58.2 (56–60.5) ng/mL 53.3 (52.2–54.4) lg/mL 1:920 0 E1, M1 A
CO6 P13671 108 57.7 (55.9–59.6) ng/mL 78.5 (77.5–79.6) lg/mL 1:1400 0 E1, M1 A
WIF1 Q9Y5W5 38.4 51.4 (39.1–67.5) ng/mL 123 (71.5–211) ng/mL 1:2.3 87 Q2
FINC P02751 550 45.6 (44.6–46.7) ng/mL 241 (233–248) lg/mL 1:5300 0 E1 A
AFAM P43652 87 40.7 (23.3–71.3) ng/mL 7.73 (6.6–9.05) lg/mL 1:200 0 E5, M1 L
IBP6 P24592 32 34.3 (34.1–34.5) ng/mL 631 (591–672) ng/mL 1:20 0 Q1
CO5 P01031 188 32.1 (31.1–33.2) ng/mL 78.4 (77.3–79.5) lg/mL 1:2400 0 E1, M1 A
APOA2 P02652 56* 22.5 (21.5–23.4) ng/mL 30.8 (30.1–31.6) lg/mL 1:1400 0 E1 A
KNG1 P01042 121 16.4 (15.8–17) ng/mL 58.9 (57.7–60.2) lg/mL 1:3600 0 E1, M1 A
APOC3 P02656 10.8 15.9 (11.3–22.3) ng/mL 71.3 (60.9–83.4) lg/mL 1:4500 0 E6 A
IBP2 P18065 31.4 11.1 (11–11.2) ng/mL 206 (196–217) ng/mL 1:18 0 Q1
TIMP1 P01033 28 4.93 (4.88–4.98) ng/mL 212 (194–233) ng/mL 1:45 0 Q1
VGFR1 P17948 110 4.64 (4.61–4.67) ng/mL 12 (10.7–13.3) ng/mL 1:2.5 98 Q1
TIMP2 P16035 21.7 3.97 (3.54–4.44) ng/mL 12 (10.9–13.2) ng/mL 1:3 53 Q2
ANGI P03950 14 3.32 (3.26–3.39) ng/mL 91.3 (89.4–93.3) ng/mL 1:27 0 E1, M1 R
ICAM2 P13598 55 2.82 (2.79–2.85) ng/mL 491 (395–611) ng/mL 1:180 0 Q1, M2
IBP3 P17936 150 2.66 (2.64–2.68) ng/mL 927 (888–967) ng/mL 1:350 0 Q1
NCAM1 P13591 110* 2.59 (2.56–2.62) ng/mL 491 (467–516) ng/mL 1:190 0 Q1
CD14 P08571 53 2.53 (2.51–2.55) ng/mL 146 (137–155) ng/mL 1:62 0 Q1
IL6RB P40189 100 2.35 (2.2–2.5) ng/mL 77.1 (73.4–80.9) ng/mL 1:33 64 Q2
RARR2 Q99969 15.8 2.29 (1.81–2.89) ng/mL 23.1 (13.8–38.8) ng/mL 1:9.4 0 Q2, M2
A2GL P02750 55 1.96 (1.52–2.54) ng/mL 1.9 (1.69–2.14) lg/mL 1:980 0 E5, M1 L
MMP2 P08253 72 1.89 (1.85–1.93) ng/mL 206 (171–247) ng/mL 1:110 0 Q1
TNF13 O75888 17 1.29 (1.27–1.32) ng/mL 70.9 (64.8–77.5) ng/mL 1:58 0 Q1
CXL14 O95715 9.4 1.26 (1.24–1.27) ng/mL 2.51 (2.32–2.7) ng/mL 1:2.1 0 Q1
TR11B O00300 120 1080 (1070–1090) pg/mL 597 (557–640) pg/mL 1.8:1 99 Q1
WFKN2 Q8TEU8 70 1.05 (1.04–1.06) ng/mL 8.61 (8.19–9.04) ng/mL 1:8.1 84 Q1
CADH3 P22223 80 1040 (965–1120) pg/mL 29.1 (26.1–32.5) ng/mL 1:28 55 Q2
TPO P40225 70 802 (744–864) pg/mL 11.5 (9.26–14.2) ng/mL 1:14 72 Q2
CXL16 Q9H2A7 35 779 (701–864) pg/mL 6.64 (5.69–7.75) ng/mL 1:8.5 43 Q2
MMP3 P08254 57 671 (659–683) pg/mL 46 (43.2–49) ng/mL 1:67 0 Q1
NOV P48745 35.7 593 (589–597) pg/mL 13.7 (12.9–14.6) ng/mL 1:23 0 Q1
CSF1R P07333 85 502 (498–507) pg/mL 634 (587–685) ng/mL 1:1300 0 Q1
C163A Q86VB7 130 494 (490–499) pg/mL 77.2 (72.8–81.8) ng/mL 1:170 0 Q1
CXCL6 P80162 8.3 452 (400–512) pg/mL 4.37 (2.43–7.86) ng/mL 1:9.2 0 Q2, M2
ADAM9 Q13443 68 351 (299–412) pg/mL 4.73 (1.91–11.7) ng/mL 1:12 75 Q2
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intraocular expression by ESTs were used to refine the model.
The Notes column in Table 2 shows the proteins that were used
to create (M1) and refine (M2) the model. The plot of AH:PL
versus MW of all proteins is shown in Figure 2. Based on the IOF,
the 93 proteins were categorized into three groups: proteins
that are primarily derived from plasma (IOF <20; 66 proteins),
proteins for which eye tissue is the principal source of synthesis
(IOF >80; 10 proteins), and proteins with contribution from
both eye tissue and plasma (IOF 20–80; 17 proteins). The data
are shown in Figure 1 and summarized in Table 2.
The dependence of the IOF on MW is illustrated in Figure
2B for four proteins with a similar AH:PL ratio: C-X-C motif
chemokine 14 (CXL14, 1:2.1), metalloproteinase inhibitor 2
(TIMP2, 1:3), Wnt inhibitory factor 1 (WIF1, 1:2.3), and
vascular endothelial growth factor (VEGF) receptor 1 (VGFR1,
1:2.5). As the MW increases from 9 kDa for CXL14, to 22 kDa
for TIMP2, to 38 kDa for WIF1, and to 110 kDa for VGFR1, the
IOF increases from 0% for CXL14 to 53% for TIMP2, to 87% for
WIF1 and to 98% for VGFR1. The data are shown in Figure 2
and summarized in Table 2.
Correlation Between Aqueous and Plasma
Concentrations of Plasma-Derived Proteins
For aqueous and plasma samples that were obtained simulta-
neously from individual subjects, the correlation coefficient
were estimated from the AH:PL ratio models for each protein.42
Using those proteins derived from plasma with an IOF of zero,
we found that low-MW proteins (less than 50 kDa) exhibited
high correlation between aqueous and plasma concentrations.
With increasing MW, the correlation between aqueous and
plasma concentrations decreased to essentially zero for
proteins with a MW of greater than 150 kDa (Fig. 3).
Rank Order of Proteins in AH Compared With
Plasma
The concentration of individual proteins in the AH and plasma
is listed in Table 2 in the order of decreasing concentration in
AH. The examination of the rank order of the most abundant
AH proteins shows that there is an order of magnitude
difference between the most abundant protein, albumin, and
the rest of the AH proteins. The fundamental difference in the
rank order between aqueous and plasma is the relative increase
of plasma-derived proteins with lower MW and the relatively
high abundance of ocular-derived proteins in AH. This shift is
highlighted in Table 3 for two examples of plasma-derived
proteins with a relatively low MW, CYTC, and beta 2
microglobulin (B2MG). The three examples of ocular-derived
proteins, pigment epithelium-derived factor (PEDF), Dickkopf-
related protein 3 (DKK3), and osteopontin (OSTP), all with
TABLE 2. Continued
Protein
Symbol UniProt ID
MW,
kDa
Aqueous Concentration Plasma Concentration
ELISA
Kit
Mean
(95% CI) Units
Mean
(95% CI) Units Ratio
IOF,
% Notes
LEG3 P17931 31 340 (287–404) pg/mL 7.64 (6.5–8.97) ng/mL 1:23 0 Q2
CCL2 P13500 8.6* 289 (282–297) pg/mL 47.7 (46.7–48.7) pg/mL 6.1:1 86 E3 A
VEGFA P15692 45 286 (283–288) pg/mL 1.53 (1.38–1.69) ng/mL 1:5.4 76 Q1
SPIT2 O43291 35 282 (240–332) pg/mL 2.45 (1.8–3.36) ng/mL 1:8.5 43 Q2
INHBA P08476 25 229 (216–242) pg/mL 698 (644–757) pg/mL 1:3 63 Q2
SIGL9 Q9Y336 36 195 (174–219) pg/mL 1.2 (0.947–1.52) ng/mL 1:6.1 61 Q2
VGFR2 P35968 160 179 (177–181) pg/mL 8.22 (7.91–8.55) ng/mL 1:46 77 Q1
GPNMB Q14956 115 159 (144–175) pg/mL 9.87 (5.89–16.6) ng/mL 1:57 50 Q2
CATL1 P07711 41 156 (125–194) pg/mL 2.53 (1.18–5.42) ng/mL 1:14 30 Q2
ANGP2 O15123 70 114 (113–115) pg/mL 2.96 (2.77–3.16) ng/mL 1:25 49 Q1
PDGFA P04085 28.9 97.6 (97.1–98.2) pg/mL 4.57 (4.05–5.15) ng/mL 1:44 0 Q1, M2
KIT P10721 98 94 (83.9–105) pg/mL 35.6 (30.1–42.1) ng/mL 1:380 0 Q2
HGFL P26927 78.4 93.5 (79.1–110) pg/mL 4.8 (4.21–5.46) ng/mL 1:52 14 Q2
MIF P14174 37.5 89.6 (88.6–90.7) pg/mL 1.51 (1.35–1.69) ng/mL 1:15 11 Q1
MMP7 P09237 28 76.4 (75.4–77.4) pg/mL 1.87 (1.67–2.11) ng/mL 1:26 0 Q1, M2
CXL10 P02778 8.6 69.7 (69–70.5) pg/mL 378 (339–420) pg/mL 1:4.8 0 Q1, M2
TIE2 Q02763 75 68.8 (67.9–69.7) pg/mL 2.73 (2.49–2.98) ng/mL 1:41 26 Q1
TR13B O14836 13 68.4 (67.8–68.9) pg/mL 1.87 (1.73–2.03) ng/mL 1:29 0 Q1, M2
GDF15 Q99988 30 57.9 (49.6–67.5) pg/mL 1.16 (0.871–1.55) ng/mL 1:20 0 Q2
MMP10 P09238 57 57.2 (56.7–57.7) pg/mL 121 (110–134) pg/mL 1:2.3 93 Q1
TNR1B P20333 75 52.7 (52.1–53.3) pg/mL 11.4 (10.5–12.3) ng/mL 1:220 0 Q1, M2
TNR1A P19438 55 47 (46.6–47.3) pg/mL 1.03 (0.947–1.12) ng/mL 1:23 31 Q1
MMP13 P45452 60 37.6 (37.3–37.8) pg/mL 581 (552–612) pg/mL 1:16 58 Q1
HGF P14210 80 33.9 (26–44.3) pg/mL 215 (115–402) pg/mL 1:6.1 90 Q2
TNR16 P08138 42.5 28.9 (28.5–29.3) pg/mL 1.02 (0.918–1.13) ng/mL 1:36 0 Q1
NTF4 P34130 28 28.5 (23.8–34) pg/mL 501 (394–638) pg/mL 1:18 0 Q2
FGF7 P21781 28 12.9 (11.3–14.8) pg/mL 147 (130–166) pg/mL 1:11 0 Q2
CCL11 P51671 8.4 10.4 (10.4–10.5) pg/mL 269 (250–290) pg/mL 1:27 0 Q1, M2
FLT3L P49771 21 10.2 (10.1–10.3) pg/mL 213 (197–230) pg/mL 1:21 0 Q1, M2
UFO P30530 80 5.72 (5.65–5.79) pg/mL 210 (193–229) pg/mL 1:38 39 Q1
IL8 P10145 16 0.95 (0.94–0.95) pg/mL 48.3 (42.8–54.6) pg/mL 1:52 0 Q1
A, Abcam; E1–E7, ELISA group 1–7; L, LSBio; M1, Model 1; M2, Model 2; Q1, Quantitative antibody microarray group 1; Q2, Quantitative
antibody microarray group 2; R, Raybiotech.
* Lowest MW of multiple forms.
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IOF greater than 95%, highlight the relatively high contribution
of proteins that are synthesized by ocular tissue.
The concept of the percent transfer, that is, how much of
the total amount of plasma protein passes into AH (percent
transfer ¼ AH concentration / plasma concentration 3 100), is
shown in Table 3 for the four plasma-derived proteins.
DISCUSSION
Although the protein component of AH is very dilute
compared with that of plasma, most of the protein mass in
AH is thought to arise from plasma. However, AH is not a
simple diffusate of plasma, because it has both qualitative and
quantitative differences in protein content relative to plasma.
By analyzing the MW of plasma-derived proteins in AH, we
found that lower-MW proteins tended to penetrate AH more
readily than higher-MW proteins. Indeed, AH concentrations of
plasma-derived proteins are a function of MW. The logarithmic
function is consistent with the model in which plasma proteins
pass into AH by diffusing through ciliary body and iris stroma
along a concentration gradient.4,5,43 Our study adds to the
mounting evidence that the blood-aqueous barrier, as it
pertains to the anterior chamber, is best thought of as a size-
dependent diffusional gradient.4,5,43 A similar model has been
proposed for entry of plasma proteins into CSF through the
blood-CSF barrier.6,7
Introducing the AH:PL versus MW logarithmic function
enables the estimation of the AH level of a plasma protein and
the calculation of the contribution of intraocular tissues to the
total aqueous concentration of the protein. By taking the IOF
of an aqueous protein into account, one may be able to assess
the protein’s relative importance to ocular physiology and the
pathogenesis of various eye diseases. Proteins with high IOF
are more likely to be derived from the corneal endothelium,
trabecular meshwork, iris, lens, and ciliary body, and represent
disease biomarkers. These proteins may serve a potential target
for further studies that look for differences in protein
concentration in AH in various pathologic ocular conditions.
In addition, our findings could be used to help understand
what occurs in conditions associated with the breakdown of
the blood-aqueous barrier. The most abundant proteins in AH,
albumin and IgG, are plasma derived and have a low IOF.
Although purely plasma-derived proteins may be important for
normal ocular physiology, their aqueous concentrations are
directly dependent on their plasma concentration and MW and
thus their ocular function is regulated by their systemic levels.
It is important to note some limitations building our model.
We assume that a protein is essentially plasma-derived if it is a
known high-abundance plasma protein and lacks a known EST
FIGURE 1. Effect of MW on the AH versus plasma protein concentration. The mean aqueous and plasma concentrations of 37 proteins as measured
by ELISA are plotted. The area of the bubble represents the MW of the protein. The dashed line indicates the AH:PL of albumin (1:300). Proteins
above the line are overrepresented (higher AH:PL) in AH relative to albumin, whereas proteins below the line are underrepresented (lower AH:PL)
in AH relative to albumin. Proteins primarily derived from plasma are shown in brown (eye-derived IOF 0–20), proteins primarily derived from eye
tissue are shown in blue (IOF 80–100), and proteins originating from both plasma and eye tissues are shown in green (IOF 20–80). Plasma-derived
proteins smaller than albumin have a higher AH:PL than albumin (above the dashed line), whereas larger plasma-derived proteins have a lower
AH:PL than albumin (below the dashed line).
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from intraocular tissues. The catalog of genes identified by EST
sequencing of a cDNA library reflects a random sample of the
mRNA present in the cell. For abundantly expressed genes, the
library provides a good indication of the gene transcription in
the tissue. However, less transcriptionally active genes might
be missed during the generation of the library. Furthermore,
transcript levels do not necessarily reflect protein levels.44
Hence, we may have missed the intraocular contribution to the
aqueous concentration for some low-abundance proteins.
However, given the overall curve fitting, we think the
intraocular contribution for the proteins used to build the
model is likely negligible.
FIGURE 2. The AH:PL as a function of MW. The AH:PL ratio for 93 proteins measured in both fluids. Proteins represented by red squares were used
to construct the model. Proteins represented by blue circles illustrate the dependence of the IOF on MW. The curve is logarithmic as a function of
MW (A), and linear when plotting MW on a log scale (B). The shaded regions show the 95% prediction interval.
FIGURE 3. Correlation between AH and plasma as a function of MW. For plasma-derived proteins with no evidence of ocular production, the
correlation between AH and plasma tends to be high when the MW is low (< 50 kDa), decreasing when the MW is between 50 and 150 kDa, and
approximately 0 for MWs above 150 kDa. The shaded region gives a 95% confidence interval for the smoothed curve.
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Another limitation of our targeted approach is that the
analysis is restricted to proteins that are available for ELISA
and/or quantitative antibody microarrays. Therefore, only a
very limited number of proteins in AH could be quantified.
Although our study was thorough, the 93 proteins we
quantified in both the AH and plasma are only a fraction of
the aqueous proteome.
Between aqueous and plasma samples collected concur-
rently, we found strong correlations in concentrations for small
proteins but poor correlations for large proteins. This suggests
that small proteins diffuse rapidly enough into AH to
quantitatively reflect the plasma concentrations. In contrast,
larger proteins diffuse far more slowly into AH so that by the
time the proteins reach the AH, the plasma concentrations
have changed sufficiently such that there is no longer
correlation between the corresponding concentrations.
In conclusion, to our knowledge, this study is the first to
simultaneously measure the protein concentration in aqueous
and plasma in a large number of proteins. Our comprehensive
analysis, demonstrating the logarithmic relationship of the MW
and the AH:PL, enables an estimate of the contribution of
intraocular tissues to the total aqueous concentration of a
protein. Moreover, taking the IOF of proteins into account may
help guide future studies of AH proteomics by providing
potential ocular-derived protein targets that are relevant to
ocular physiology and disease.
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